Pharmaceutical major Mylan NV announced that it has received approval from Indian drugs regulator DCGI to manufacture and market

Pharmaceutical major Mylan NV announced that it has received approval from Indian drugs regulator DCGI to manufacture and market its remdesivir for restricted emergency use in the country for the treatment of Covid-19.

The drug will be priced at Rs 4,800 per 100 mg vial and would be available to the patients in this month.

Remdesivir The company joins domestic pharma firm Cipla and Hetero who have already received permission from the Drug Controller General of India (DCGI) to manufacture and market remdesivir for the treatment of Covid-19.

The DCGI has approved the company's remdesivir 100 mg per vial for restricted emergency use in India amid the Covid-19 pandemic, Mylan said in a statement.

The drug is approved for the treatment of Covid-19 in adults and children hospitalised with severe presentations of the disease, it added.

Remdesivir"The drug will be launched under the brand name 'Desrem' in India and will be available to patients in July at a price of Rs 4,800, which is more than 80 per cent less than the price at which the branded version of this product will be available to governments in the developed world," Mylan said.

Domestic pharma major Cipla has already said it will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial.

Hetero has also said that it has fixed a maximum retail price of Rs 5,400 per vial for the drug.